Women make testosterone, too. It’s produced in the ovaries and adrenal glands and contributes to multiple physiologic processes. This page explains when and how testosterone may be discussed for women, what current medical groups say, why regulatory status matters, and what to ask your clinician. Educational only; not medical advice.
Key Points
-
Major medical societies agree that the only evidence-based indication for systemic testosterone therapy in women is hypoactive sexual desire disorder (HSDD) in postmenopausal women, after a biopsychosocial evaluation.
-
In the U.S., there is no FDA-approved testosterone product for women. Any use relies on off-label adaptation of approved male formulations or on compounded products, which are not FDA-approved.
-
Claims about improved energy, muscle growth, “anti-aging,” or general wellness are not established indications and should be avoided. Care must be individualized, goal-focused, and monitored.
What Do Guidelines Actually Say?
A 2019 Global Consensus Position Statement (endorsed by The Endocrine Society, The Menopause Society, ISSWSH, and others) concluded that systemic testosterone may be considered for postmenopausal women with HSDD, with dosing that aims to keep blood levels within the normal premenopausal range. It does not support testosterone for mood, cognition, musculoskeletal performance, or general “vitality.” imsociety.org
The Menopause Society later summarized practical points for identifying HSDD, dosing (typically low-dose transdermal), and monitoring, again emphasizing that HSDD is the evidence-based indication. Huntington Hospital
U.S. Regulatory Status (Why It Matters)
-
No FDA-approved testosterone product for women (including for menopausal symptoms). When testosterone is prescribed to a woman, it’s either an off-label, low-dose use of an approved male formulation or a compounded preparation. Compounded products aren’t reviewed by the FDA for safety, effectiveness, or quality. ACOG
-
Professional groups advise not to use testosterone pellets for women due to removal issues and limited safety data; if testosterone is considered, other routes are preferred. LWW
Setting Expectations (and Staying Safe)
If you and your clinician are evaluating low sexual desire, the process typically includes:
-
history, exam, and psychosocial assessment; 2) addressing nonhormonal contributors; 3) considering on-label options; and only then 4) discussing off-label low-dose testosterone when HSDD is diagnosed, with informed consent and a monitoring plan. ISSWSH
Note: The FDA recently updated men’s testosterone labels (e.g., blood-pressure warnings, keeping the limitation against age-related “low T”). This underscores why indication-aligned use and monitoring matter for any testosterone product. U.S. Food and Drug Administration
What We Do (Our Approach)
At Body Balance Medical, we start with evaluation first. If concerns include low sexual desire, we follow current guidance: clarify diagnosis, discuss nonhormonal and on-label options, and, where appropriate, review the off-label nature of testosterone for women, potential benefits/uncertainties, dosing targets that avoid supraphysiologic levels, and monitoring. We do not promote performance or anti-aging claims, and we avoid prohibited or non-approved products.
FAQs
Is testosterone therapy “for women” a standard treatment?
Only in a narrow situation: postmenopausal HSDD after evaluation. Outside of that, routine use isn’t supported by current consensus statements. imsociety.org
Are there FDA-approved testosterone products for women?
No. Any use is off-label or compounded (not FDA-approved). Discuss risks, alternatives, and monitoring with your clinician. ACOG
What about pellets or “optimization” programs promising energy and muscle?
Guidelines caution against pellets and against performance/anti-aging claims. Stick to diagnosis-led care and physiologic dosing if therapy is considered. LWW
Are there other options for low sexual desire?
Yes—depending on the cause. Your clinician may discuss biopsychosocial strategies and FDA-approved non-testosterone treatments for certain premenopausal women, among other options. ISSWSH
